Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Profit After Tax (2016 - 2026)

Ironwood Pharmaceuticals' Profit After Tax history spans 16 years, with the latest figure at -$2.3 million for Q4 2025.

  • On a quarterly basis, Profit After Tax fell 200.89% to -$2.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $24.0 million, a 2629.2% increase, with the full-year FY2025 number at $24.0 million, up 2629.2% from a year prior.
  • Profit After Tax hit -$2.3 million in Q4 2025 for Ironwood Pharmaceuticals, down from $40.1 million in the prior quarter.
  • Over the last five years, Profit After Tax for IRWD hit a ceiling of $391.3 million in Q2 2021 and a floor of -$1.1 billion in Q2 2023.
  • Historically, Profit After Tax has averaged -$13.7 million across 5 years, with a median of $30.3 million in 2022.
  • Biggest five-year swings in Profit After Tax: plummeted 2964.58% in 2023 and later skyrocketed 2844.07% in 2025.
  • Tracing IRWD's Profit After Tax over 5 years: stood at $41.4 million in 2021, then rose by 18.11% to $48.9 million in 2022, then tumbled by 103.57% to -$1.7 million in 2023, then skyrocketed by 229.28% to $2.3 million in 2024, then crashed by 200.89% to -$2.3 million in 2025.
  • Business Quant data shows Profit After Tax for IRWD at -$2.3 million in Q4 2025, $40.1 million in Q3 2025, and $23.6 million in Q2 2025.